We are international

The IMF is pleased to present the most comprehensive coverage of the XIth International Myeloma Workshop.

Day 1 Genetics Day 2 Novel treatment approaches
  Microenvironment   Frontline treatment of Myeloma
  Bone Disease   Debate I (Importance of CR)
      Oral presentations I
      Oral presentations II

Day 3 New treatment development Day 4 Oral presentations III
  Stem cell transplant   Debate II - Role of Transplant
  Other plasma cell dyscrasias   Current and Future Perspectives


KOS 2007
previous     next      view all

06.27.07   KOS 2007: The Treatment of Relapsed and Refractory Myeloma: Focus on Bortezomib and Bortezomib-based Combinations
Paul Richardson, MD
Medical Oncology
Dana Farber Cancer Institute
Harvard Medical School
Boston, MA, USA

06.27.07   KOS 2007: Lenalidomide for the Treatment of Relapsed or Refractory Myeloma
Donna Weber, MD
The University of Texas MD Anderson Cancer Center
Houston, TX, USA

06.27.07   KOS 2007: Impact of novel agents in patients with poor prognosis myeloma defined by unfavorable cytogenetics, high age, and renal failure
Heinz Ludwig, MD
Department of Medicine I
Center of Oncology and Hematology
Vienna, Austria

06.27.07   KOS 2007: International Staging System for Multiple Myeloma
Philip Greipp, MD
Mayo Clinic
Internal Medicine
Rochester, Minnesota

06.27.07   KOS 2007: The Role of Thalidomide in Myeloma Patients Eligible for High-Dose Therapy
Michele Cavo, MD
Seràgnoli Institute of Hematology and Medical Oncology
Bologna UniversitySchool of Medicine

06.27.07   KOS 2007: Role of Bortezomib in Myeloma Patients Eligible for High-Dose Therapy
Sundar Jagannath, MD
St. Vincent's Comprehensive Cancer Center
New York, NY, USA

06.27.07   KOS 2007: The Role of Lenalidomide in Myeloma Patients Eligible for High Dose Therapy
Vincent Rajkumar, MD
Division of Hematology
Mayo Clinic
Rochester, Minnesota, USA

06.27.07   KOS 2007: Frontline Treatment in Patients Not Eligible for Stem Cell Transplant
Thierry Facon, MD
Lille, France

06.27.07   KOS 2007: Management of Toxicities from Novel Agents
Mohamad Hussein, MD
Multiple Myeloma Clinical Research Clinical Director
H. Lee Moffitt Cancer & Research Institute
Tampa, Florida, USA

06.27.07   KOS 2007: Prognostic Factors for Multiple Myeloma in the Era of Novel Therapies
Joan Bladé
Hematology Department
Institut of Hematology and Oncology
IDIBAPS, HospitalClínic
Barcelona, Spain

previous     next      view all